Literature DB >> 21396853

Polymorphisms and haplotypes in caspases 8 and 9 genes and risk for prostate cancer: a case-control study in cohort of North India.

Ginu P George1, Raju K Mandal, Pravin Kesarwani, Satya N Sankhwar, Anil Mandhani, Rama D Mittal.   

Abstract

OBJECTIVE: Despite the potential importance of apoptosis pathways in prostate tumor etiology, little has been published regarding prostate tumor risk associated with common gene variants in caspases (CASP). Normal variations within the sequence of apoptotic genes may lead to suboptimal apoptotic capacity and therefore increased cancer risk.
MATERIALS AND METHODS: Using data from a hospital-based case-control study conducted by Sanjay Gandhi Post Graduate Institute of Medical Science, India, from 2007 to 2009, we evaluated risk of prostate cancer (CaP) in 165 patients and age-matched 205 healthy controls. We genotyped the functional IVS12-19G/A, D302H, -678del, and -652 6N ins/del polymorphisms in the promoter of CASP 8 and -293del, -1263A/G in CASP 9 genes.
RESULTS: A significant increased risk for CaP was found for the CASP 8 IVS12-19G/A heterozygous genotype (P = 0.02; OR = 1.69) as well as for the variant allele carriers (P = 0.04; OR = 1.56). Also the CASP 9 -1263A/G showed lower risk for both heterozygous and variant allele carrier genotypes (P = 0.002; OR = 0.45 and P = 0.05; OR = 0.66 respectively). CASP 9 -1263A/G was also found to be associated with increased risk with bone metastasis. Furthermore, a significant additive interaction between CASP 8 IVS12-19G/A polymorphism and tobacco smoking was observed with CaP risk.
CONCLUSION: These results suggested that the CASP 8 IVS12-19G/A and CASP 9 -1263 polymorphism may be involved in etiology of CaP and thus could be implicated as a marker for genetic susceptibility in North Indian population.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396853     DOI: 10.1016/j.urolonc.2010.08.027

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  6 in total

1.  Caspase 8 polymorphisms contribute to the prognosis of advanced lung adenocarcinoma patients after platinum-based chemotherapy.

Authors:  Di Liu; Wen Xu; Xi Ding; Yang Yang; Yanlin Lu; Ke Fei; Bo Su
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

2.  Effects of Caspase 9 Gene Polymorphism in Patients with Prostate Cancer.

Authors:  Seda Gulec Yilmaz; Faruk Yencilek; Asif Yildirim; Esin Yencilek; Turgay Isbir
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

3.  Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.

Authors:  Ji Qian; Hui-Qi Qu; Lixin Yang; Ming Yin; Qiming Wang; Shaohua Gu; Qihan Wu; Xueying Zhao; Wenting Wu; Junjie Wu; Xiaoming Tan; Wenqing Chen; Haijian Wang; Jiucun Wang; Weiwei Fan; Hongyan Chen; Baohui Han; Daru Lu; Qingyi Wei; Li Jin
Journal:  Oncologist       Date:  2012-07-27

4.  A meta-analysis of caspase 9 polymorphisms in promoter and exon sequence on cancer susceptibility.

Authors:  Wei Xu; Shengqiang Jiang; Yuanyuan Xu; Bo Chen; Yan Li; Feng Zong; Weihong Zhao; Jianqing Wu
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

5.  CASP8 -652 6N insertion/deletion polymorphism and overall cancer risk: evidence from 49 studies.

Authors:  Jiarong Cai; Qingjian Ye; Suling Luo; Ze Zhuang; Kui He; Zhen-Jian Zhuo; Xiaochun Wan; Juan Cheng
Journal:  Oncotarget       Date:  2017-05-25

6.  Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.

Authors:  Rajani Rai; Kiran L Sharma; Surbhi Sharma; Sanjeev Misra; Ashok Kumar; Balraj Mittal
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.